US equities
|
SPCX
$167.12
▲+5.13%
NVDA
$236.99
▲+1.30%
MU
$1,065.86
▼-0.84%
TSLA
$375.68
▲+1.37%
MSFT
$525.71
▲+1.58%
INTC
$116.90
▼-2.04%
SNDK
$1,722.13
▲+0.12%
META
$742.13
▲+1.93%
SPCX
$167.12
▲+5.13%
NVDA
$236.99
▲+1.30%
MU
$1,065.86
▼-0.84%
TSLA
$375.68
▲+1.37%
MSFT
$525.71
▲+1.58%
INTC
$116.90
▼-2.04%
SNDK
$1,722.13
▲+0.12%
META
$742.13
▲+1.93%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
3.100
+0.220 (+7.64%)
Delayed Quote
Updated: 10:04 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
32
33
Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Aims to Deliver Safer Alternative for Nicotine Experience
May 19, 2022
Via
CannabisNewsWire
Topics
Death
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Aims to Deliver Safer Alternative for Nicotine Experience
May 19, 2022
Via
Investor Brand Network
Topics
Death
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Devoting Research, Product Development to Make Drug Substances More Effective
May 13, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs
↗
April 21, 2022
Via
Benzinga
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry
May 11, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands
May 06, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands
May 06, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands
May 05, 2022
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands
May 05, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH
April 29, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform
April 28, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform
April 28, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data
April 27, 2022
Via
Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research
↗
April 26, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria expects to begin dosing this summer as part of a human...
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices
April 25, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices
April 25, 2022
Via
CannabisNewsWire
Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
↗
April 22, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
April 21, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
April 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
April 21, 2022
- 25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
53 Biggest Movers From Yesterday
↗
April 21, 2022
Gainers ION Geophysical Corporation (NYSE: IO) shares surged 91.2% to settle at $0.6980 on Wednesday. ION Geophysical was awarded a five-year contract by Brunei Shell Petroleum...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
↗
April 20, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
↗
April 20, 2022
Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday. AlloVir, Inc. (NASDAQ: ALVR) shares climbed 39% to $7.52...
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
April 19, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
April 19, 2022
Via
CannabisNewsWire
Lexaria (NASDAQ: LEXX) Advances Human Nicotine Study, Announces New Program with Altria
April 19, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Commences Multi-Week Human Clinical Hypertension Study
April 19, 2022
- HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits - This study is designed to enhance Lexaria's probabilities of success with its...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Announces Positive Results From Hypertension Study
↗
April 18, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances its Human Nicotine Study and Announces New Nicotine Formulation Creation and Evaluation Program with Altria
April 18, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience (NASDAQ: LEXX) Announces Positive Results from Hypertension Study
April 18, 2022
Via
Investor Brand Network
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
32
33
Next >
